[ CSPS Pharmaceuticals, Inc. ] [ SPYDER ]

Back to Forum



SIDDCO is now hiring BS, MS, and Ph.D. level chemists with a minimum of two years experience in combinatorial drug discovery. Experience in synthetic organic chemistry and medicinal chemistry is desirable. SIDDCO is a new, privately held company financed by collaborative contract research with established pharmaceutical companies. SIDDCO offers competitive salaries, stock options, and high quality of life in beautiful, affordable Tucson, Arizona. Qualified candidates should send their c.v. and list of references to :

Open Chemistry Positions
Systems Integrated Drug Discovery Company
2461 E. Calle Sin Pecado
Tucson, Arizona 85718

Posted: 6 July, 1997

Job Openings at 3DP

3-Dimensional Pharmaceuticals, Inc. has several immediate openings for computational chemists and/or computer scientists to join the DirectedDiversity group.

The successful candidates will participate in the development of state-of-the-art computational tools in the areas of molecular modeling, informatics and computational intelligence. Proficiency in C++ under UNIX and extensive experience in large scale software engineering, algorithm design, GUI development and design, and chemical computation is essential, particularly in the areas of protein-ligand interactions, molecular similarity, chemical diversity and QSAR. Experience with Java and Web programming is a plus.

Positions are available at all levels (BS, MS, PhD). If you are interested, please send your resume by snail- or e-mail to the address indicated below. Thanks.

Dimitris K. Agrafiotis, PhD
3-Dimensional Pharmaceuticals, Inc.
665 Stockton Drive, Suite 104
Exton, PA 19341
E-mail: dimitris@3dp.com
Tel: (610) 458-6045
Fax: (610) 458-8249

Posted: 11 May 1997

Two post-doc positions in phage-display technology.

I am seeking individuals at the post-doctoral level with a strong background in molecular genetics and some experience with protein expression and purification. Both positions are available from September/October of 1997 and will run for three years. The work on both positions makes use of phage display technlogy and a close collaboration between the two post-doctoral fellows is expected.

Job descriptions: 1) "Generation of recombinant antibody-toxins directed against tumor associated peptide/HLA complexes with T cell receptor-like specificity"

Expression of specific peptides in complex with MHC molecules has been shown to be associated with cancer. For example, human melanomas express tumor-specific peptides that are presented to the immune system in complex with class I HLA-A2 molecules. Specific targeting of drugs to these cells by using these specific peptide/HLA complexes will be a useful and promising approach. In a model system, we have recently generated a recombinant antibody-toxin fusion protein targeted to a peptide/MHC with T cell receptor-like specificity and demonstrated that killing of antigen-presenting cells occured in a peptide specific maner(*). The results suggest that such an approach is feasible to apply to novel immunotherapeutic strategies against human cancer. * Andersen, P. S. et al (1996) PNAS 93(3), 1820-1825. * Stryhn, A. et al (1996) PNAS 93, 10338-10342. * Reiter, Y. et al (1997) PNAS April issue.

2) "Novel approaches in the study of differential gene expression by developing the phage display technology"

I have been funded together with prof. Brian F. C. Clark , University of Aarhus, to develop the technology of displaying antibody fragments on filamentous phage in a way that allows us to obtain antibodies directed against gene products that are expressed differentially in human epidermal keratinocytes upon differentiation in vitro in cell cultures. Such gene expression will reflect the cellular process of differentiation. Thus with a panel of antibodies against the corresponding proteins it will be posible to gain information on the differentiation of the keratinocytes. We have recently developed a method with potential for such analysis(*) but a larger antibody library is necessary, since the method requires one single source library from which antibodies with high affinities can be selected against a broad variety of antigens. Therefore, one primery goal is to generate a large human naive library of antibody fragments displayed on filamentous phage. * Stausbl-Grn, B. et al (1996) FEBS letters 391, 71-75.

Further information may be obtained from professor Jan Engberg. Please address - BEFORE THE 1st OF JUNE - applications, which should contain a full CV, a short summary of research experience and the full postal and e-mail addresses and fax and phone numbers of three references to:

Professor Jan Engberg, The Royal Danish School of Pharmacy, Department of Biological Sciences, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
Phone: +45 35 37 08 50 ext 384. Direct: +45 35 37 66 67 await tone, then press 384
Fax: +45 35 37 57 92.
e-mail: je@charon.dfh.dk

Posted: 21 April 1997

Vertex Pharmaceutical Incorporated, combining the disciplines of biology, chemistry and biophysics, produces novel therapeutics that play a key role in the treatment of many diseases including cancer multidrug resistance, hemoglobin disorders, inflammation, and HIV infection and AIDS. We are seeking to fill the following positions:


As a broadly experienced and highly creative synthetic chemist, you will apply your knowledge of organic reactions to automated synthesis of targeted compound libraries. You will interface closely with medicinal and peptide chemists and with the biological assay and computational chemistry groups. Your extensive experience with a variety of biologically relevant molecules, excellent communication skills, and strong desire to be part of the emerging field of automated synthetic chemistry will serve you well in this high visibility position. NON-PH.D APPLICANTS must have a strong background in synthetic organic chemistry with a minimum of two years of post-bachelor degree, full time bench laboratory experience and hands-on familiarity with programmable laboratory equipment. PH.D. APPLICANTS must also have a very strong background in synthetic organic chemistry, at least 2+ years post graduate experience, preferably in industry. A strong publication record is highly desirable.


As a member of our medicinal chemistry group you will work closely with colleagues in combinatorial chemistry, biology, biophysics and computational chemistry in an intense and challenging interdisciplinary environment. Your desire to apply insights from a broad variety of areas to the process of drug design and strong commitment to experimental science are essential for this position. Applicants must have a degree in synthetic organic chemistry with at least 2+ years of post-graduate experience preferably in industry.

Please send your resume to:

Vertex Pharmaceuticals Incorporated
Recruiting Manager Code: mol.reps
130 Waverly Street Cambridge,
MA USA 02139
FAX: (617) 577-6645
e-mail: recruiting@vpharm.com.

Visit our homepage at http://www.vpharm.com

Posted: 4 April 1997

The Antibody Engineering group CESAME, based in the Department of Pathology, University Hospital Maastricht, the Netherlands, has available positions for :

You will be involved in network research projects financed by the European Community as part of the 4th Biotechnology Framework. The research in Maastricht focuses on the development of strategies for the immunotherapy of cancer :

(1) Recombinant bispecific antibodies for the treatment of B-cell non-Hodgkin's disease. This project involves the design and construction of 'diabodies', antibody fragments with two binding sites, using phage display and expression in bacteria (McGuinness et al. Nat Biotechnol 14, 1149-54, 1996). These proteins will be tested for their in vitro en in vivo T-cell-retargeting capacity.

(2) MHC-peptide complex specific antibodies for tumor targeting. The candidate will study the possibility to derive human antibodies specific for recombinant MHC-Class I molecules complexed to tumor-associated peptides (similar to Andersen et al. Proc Natl Acad Sci USA 93, 1820-24, 1996, for class II). The tumor-targeting efficacy of these antibodies will be tested in close collaboration with other partners of the programme.

(3) Intracellular antibodies : The candidate will be involved in designing new antibody scaffolds, creating synthetic phage antibody libraries and selecting high affinity ligands to certain tumor-associated intracellular targets (Persic et al Gene 187:1-16, 1997).

You will be based in the Department of Pathology, University Hospital Maastricht, in the Netherlands, working in the multidisciplinary research team CESAME, in which antibody engineering en phage display are being used as key technologies to derive useful immunotargeting molecules (Hoogenboom, TIBTECH 15, 62-70; 1997).

Applicants have a PhD in a relevant areas (molecular immunology, protein engineering, oncology) or equivalent experience; additional postdoctoral experience abroad is a major advantage. Expertise in molecular biology and familiarity with protein biochemistry are essential.

Salary is according to age and experience within band 10 (to max Dfl. 6.092,-). Appointments are full time, for 2-3 years, and available within the next 4 months.

More information about these positions may be obtained from dr. ir. H.R.J.M. Hoogenboom, tel. 31-43-3874630, or via E-mail : hho@lpat.azm.nl

Please send, before the 1st of May,

to dr. ir. H.R.J.M. Hoogenboom,
Department of Pathology,
Academisch Ziekenhuis Maastricht,
P.O.Box 5800, 6202 AZ Maastricht,
the Netherlands
or FAX 31-43-3876613.

Posted: 4 April 1997

The Queen's University of Belfast

School of Biology and Biochemistry

Postgraduate Research Studentships 1997-98

The School of Biology and Biochemistry offers excellent facilities for a wide range of fundamental and applied research extending from molecular and cellular biology to ecology. Applications are invited from UK and other EU candidates who have or expect to obtain a relevant First or Upper Second Class Honours Degree or equivalent qualification.

Studentships are available in the following areas commencing October 1997:

Study of cell permeable peptides by combinatorial libraries

Combinatorial library approaches to studying the role of proteinases in programmed cell death (apoptosis)

Discovery of novel cell adhesion receptors and ligands by combinatorial library methods

Autoantibodies to apolipoproteins in atherosclerosis

Biochemistry and genetics of organosulphonate metabolism by microorganisms

Enzyme activity as an indicator of nutrient status of phytoplankton or seaweeds

Applications from well qualified students in other areas of interest within the School will also be considered. Inquiries from non-EU students who expect to have appropriate funding are also very welcome.

Further details and application forms are available from
The Director,
School of Biology and Biochemistry,
The Queen's University of Belfast,
Medical Biology Centre,
97 Lisburn Road, Belfast BT9 7BL
Fax +44-1232-236505
Email sobb.office@qub.ac.uk OR contact the appropriate staff email address above.

All applications for admission must be received by the Admissions Office, The Queen's University of Belfast no later than 15 MAY 1997.

The first allocation of studentships to outstanding applicants will be made in APRIL so candidates are encouraged to apply early.

The University is a charity established in 1845 to advance education.

Posted: 4 March 1997

We seek a broadly trained Ph.D. level molecular biologist/biochemist to interact with combinatorial chemists, plant molecular biologists and bacterial geneticists in the design and implementation of screens and selections for bio- or catalyticly active compounds. The successful candidate will provide input into chemistry programs at their inception allowing a melding of assay requirements with synthetic design parameters. Moreover, we envision that the principal investigator will utilize a wide array of molecular techniques such as encoding protocols, bead technologies, phage display, aptamer amplification and immunological procedures to accomplish group objectives. Appreciation of the power of genetic selections and visual screens may lead the candidate to novel approaches for discovery of chemical leads.

Please send c.v. and name of three references to:

Dr. Pablo A. Scolnik
Central Research P.O. BOX 80402
Wilmington, DE 19880-0402

Posted: 4 February 1997

If you are a postdoc from an Eastern European country, are under 40 years old and want to do non-clinical medical research in the UK for up to 12 months, then read on.

I am looking for candidates from NATO cooperation countries to apply jointly with me to THE ROYAL SOCIETY/NATO POSTDOCTORAL FELLOWSHIP PROGRAMME. If we are successful, the candidates will receive an award to work in my laboratory here in the UK for up to 12 months.

POSTDOCTORAL SCIENTISTS from ONLY THE FOLLOWING NATO cooperation partner countries are eligible:

Albania, Armenia, Azerbaijan, Belarus, Bulgaria, Czech Republic, Estonia, Georgia, Hungary, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Poland, Romania, Russia, Slovak Republic, Slovenia, Tajikstan, Turkmenistan, Ukraine, Uzbekistan and the Former Yugoslav Republic of Macedonia.

Under this programme, fellowship holders receive an award which covers living costs in the UK, together with a contribution towards travel costs and research expenses.

I am particularly interested to hear from candidates in the following fields:

  1. Intracellular signalling pathways.
  2. Recombinant protein expression and mutagenesis.
  3. Mammalian cell culture.
  4. Combinatorial libraries (phage display, peptide libraries, etc.).
  5. Solid-phase organic chemistry.

For details of my own research interests, please consult the URL http://web.qub.ac.uk/bb/awpage/awproj.html or look at my web page.
Andrew Wallace,Ph.D.
Queens University Belfast
N. Ireland (UK)

Posted: 26 January 1997

Marcus & Associates, Executive Search Consultants, specializes in the recruitment of scientific and management personnel to the pharmaceutical and biotechnology industries.


Reporting to the Sr. Director, Medicinal Chemistry, this scientific role represents an outstanding opportunity to build a combinatorial chemistry effort within the Medicinal Chemistry dept., focusing on drug discovery and the automated synthesis of chemical libraries for screening compounds.

This dynamic, financially sound, public biopharmaceutical company located in San Diego currently has this newly created position available due to current expansion.

Salary range: $60.0 - $75.0K based on academic and work experience; outstanding stock option package; relocation assistance.


This high visibility position, reporting to the Director, Combinatorial Chemistry, will design and develop methods for the automated synthesis of organic compounds; you will be responsible for collaborating with diverse groups of scientist within drug discovery to develop lead compounds towards the attainment of program objectives; in addition you will assist in the development of integrated computer and robotic systems for automated synthesis; this position requires the ability to supervise research associates.

This blue-chip pharmaceutical company located in the New England area is currently seeking somebody to join their state-of-the-art combinatorial drug discovery group.

Salary range: $65.0 - $90.0K depending on academic and work experience; excellent benefits package; relocation assistance.

These positions require a Ph.D., Medicinal/Organic Chemistry; working knowledge of solid/solution phase synthesis; experience working with small organic molecules; interest or experience in the combinatorial chemistry field; excellent oral and written skills along with the desire to stay active in the scientific community.

Please send resume/C.V. in strict confidence to:
Dean Kaplan
Senior Recruitment Specialist
Marcus & Associates
Millwood Business Center
358 Saw Mill River Road
Millwood, NY 10546
Tel:(914) 941-7100
Fax: (914) 941-8629

Posted: January 14, 1997